To investigate the association between bispecific antibodies targeting BCMA and GPRC5D and the development of Campylobacter spp. infections in patients with relapsed/refractory multiple myeloma, highlighting the significance of this link in the context of existing literature.
Key Findings:
Nine patients developed Campylobacter infections, including 5 bloodstream and 5 gastrointestinal episodes, out of 85 patients.
The incidence of Campylobacter infections was notably high in this immunocompromised cohort.
Hypogammaglobulinemia was identified as a significant risk factor for these infections.
Interpretation:
The findings indicate a concerning link between bispecific antibody therapy and increased risk of Campylobacter infections, highlighting the need for preventive strategies in this vulnerable population and potential implications for clinical practice.
Limitations:
The study is retrospective and may be subject to biases, affecting the ability to establish causality.
Sample size is relatively small, limiting generalizability.
Conclusion:
The study underscores the importance of monitoring infection risks in patients receiving bispecific antibodies for multiple myeloma and suggests the need for targeted preventive measures, emphasizing the necessity for further research to validate these findings.
by Idoia Bilbao, María Ansón, Sara Villar, Iñigo Pineda, Laura Gárriz, Manuel Pina-Sánchez, Luis-Esteban Tamariz-Amador, Paula Rodríguez-Otero, José Ramón Yuste, José L del Pozo
